Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy

被引：0
|
作者：
Pamela Mangat
Samuel Whittle
Les Cleland
Vidya Limaye
机构：
[1] Royal Adelaide Hospital,Rheumatology Department
[2] The Queen Elizabeth Hospital,undefined
[3] Royal Adelaide Hospital,undefined
来源：
Clinical Rheumatology | 2008年 / 27卷
关键词：
Angiography; Anti-TNFα; Neuropathy; Vasculitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Anti-tumour necrosis factor alpha therapy has led to significant advancement in the treatment of rheumatological disease. Rarely, anti-TNFα antagonists have been associated with vasculitis, predominantly cutaneous leukocytoclastic vasculitis. We present the first case of angiographically-confirmed digital vasculitis occurring as a late complication of etanercept therapy. Our case adds to the limited repertoire of case reports of anti-TNFα induced vasculitis and highlights the potential risk of this serious complication occurring up to several years after initiation of these agents.
引用
收藏
页码：1593 / 1595
页数：2
相关论文
共 50 条
  • [41] Aseptic meningitis in a patient receiving treatment with anti-tumour necrosis factor alpha
    Hamilton, Alexander J.
    Gutowski, Nicholas J.
    JOURNAL OF NEUROLOGY, 2011, 258 (06) : 1174 - 1175
  • [42] Anti-tumour necrosis factor therapy is a risk factor for certain subtypes of chronic rhinosinusitis
    Leonard, C. G.
    Masih, C.
    McDonald, S.
    Taylor, G.
    Maiden, N.
    Leyden, P. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S148 - S148
  • [43] Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis
    Puechal, X.
    Miceli-Richard, C.
    Mejjad, O.
    Lafforgue, P.
    Marcelli, C.
    Solau-Gervais, E.
    Steinfeld, S.
    Villoutreix, C.
    Treves, R.
    Mariette, X.
    Guillevin, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (06) : 880 - 884
  • [44] DRUG SURVIVAL OF SECOND BIOLOGIC DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON OF A SECOND ANTI-TUMOUR NECROSIS FACTOR WITH A SECOND NON-ANTI-TUMOUR NECROSIS FACTOR AFTER DISCONTINUATION OF A FIRST ANTI-TUMOUR NECROSIS FACTOR
    Wilke, Thomas
    Mueller, Sabrina
    Majer, Istvan
    Heisen, Marieke
    Fuchs, Andreas
    Maywald, Ulf
    RHEUMATOLOGY, 2016, 55 : 105 - 105
  • [45] Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy
    Rosner, I.
    Haddad, A.
    Boulman, N.
    Feld, J.
    Avshovich, N.
    Slobodin, G.
    Rozenbaum, M.
    RHEUMATOLOGY, 2007, 46 (09) : 1508 - 1508
  • [46] Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy
    Ringrose, J. S.
    Sanche, S. E.
    Taylor-Gjevre, R. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (05) : 790 - 794
  • [47] Development of systemic lupus erythematosus following anti-tumour necrosis factor therapy
    Sun, S
    Barr, SG
    Martin, LO
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 422 - 422
  • [48] Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis
    Leonard, C. G.
    Masih, C.
    McDonald, S.
    Taylor, G.
    Maiden, N.
    Leyden, P. J.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2016, 130 (06): : 560 - 564
  • [49] Anti-tumour necrosis factor-α therapy in heart failure:: Future directions
    Balakumar, Pitchai
    Singh, Manjeet
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 (06) : 391 - 397
  • [50] Anti-tumour necrosis factor therapy in clinical practice: what is advance and what is not?
    D'Haens, G
    IMMUNOLOGICAL DISEASES OF LIVER AND GUT, 2004, 135 : 267 - 270
12345